Equillium (EQ) FCF Margin (2023 - 2024)
Equillium (EQ) reported FCF Margin of 75.2% for Q4 2024, down 1333.0% year-over-year from 6.1% in Q1 2024, and down 19.44% quarter-over-quarter from 62.96% in Q3 2024.
Equillium (EQ) FCF Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has 2 years of FCF Margin data on file, last reported at 75.2% in Q4 2024.
- FCF Margin for Q4 2024 came in at 75.2%, down 1333.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 521.86% (down 47502.0% YoY), and the FY2024 annual result was 46.5%, up 1400.0% from the prior year.
- FCF Margin fell to 75.2% in Q4 2024 per EQ's latest filing, from 62.96% in the prior quarter.
- Over five years, FCF Margin peaked at 5.11% in Q2 2024 and troughed at 90.04% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -75.20% |
| Sep 30, 2024 | -62.96% |
| Jun 30, 2024 | 5.11% |
| Mar 31, 2024 | -82.88% |
| Dec 31, 2023 | -61.87% |
| Sep 30, 2023 | -21.52% |
| Jun 30, 2023 | -68.12% |
| Mar 31, 2023 | -90.04% |